Dabrafenib [1195765-45-7]
D0004
Estimated Purity≥98%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NameDabrafenib [1195765-45-7]
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥98%
- Formatsoluble in DSMO
- Scientific DescriptionB-Raf and c-Raf inhibitor.; GSK2118436A
- Storage Instruction-20°C
- UNSPSC12352200
References
- Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668. Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957. Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384.